NeuroOne Medical Technologies Corporation (NMTC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

NeuroOne Medical Technologies Corporation (NMTC) is down 23.7% since the beginning of the year. At $3 per share, NMTC is trading 50.1% below its 52-week high of $7. Investors who bought $1,000 worth of NMTC shares 5 years ago would now be looking at an investment worth $77.

NeuroOne Medical Technologies Corporation (NMTC) has returned -23.70% so far this year and 3.76% over the past 12 months.

Based on dividend-adjusted daily data since Sep 18, 2017, NMTC's average daily return is +0.08%, while the average monthly return is +0.08%. At this rate, an investment would double in approximately 72.2 years.

Historically, 42% of months were positive and 58% were negative. The best month was Aug 2022 with a return of +116.1%, while the worst month was Mar 2022 at -45.0%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, NMTC closed higher 43% of trading days. The best single day was Feb 25, 2019 with a return of +51.9%, while the worst single day was Mar 28, 2022 at -46.9%.

NeuroOne Medical Technologies Corporation has an annualized alpha of 10.56%, beta of 0.62, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 20, 2017.

• This stock participated in 133.00% of S&P 500 Index downside but only -26.16% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.62 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NMTC ranks 44 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for NeuroOne Medical Technologies Corporation (NMTC) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the NeuroOne Medical Technologies Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the NeuroOne Medical Technologies Corporation was 98.41%, occurring on Apr 9, 2025. The portfolio has not yet recovered.

The current NeuroOne Medical Technologies Corporation drawdown is 97.86%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of NeuroOne Medical Technologies Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how NeuroOne Medical Technologies Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.